Edwards Lifesciences (EW) Revenue — Quarter Ended Mar 31, 2025
Revenue for the quarter increased compared with the prior quarter and the same period a year earlier. The company continued to show sequential and year-over-year growth.
Key takeaway
Quarter ended Mar 31, 2025 · FY2025 Q1
Revenue for the quarter increased compared with the prior quarter and the same period a year earlier. The company continued to show sequential and year-over-year growth.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.4B
Revenue reported for this quarter.
Quarter-over-quarter
+1.9%
Change from the immediately preceding quarter.
Year-over-year
+6.2%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.5B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2024 | $1.4B | +4.4% |
| Sep 30, 2024 | $1.4B | +11.9% |
| Dec 31, 2024 | $1.4B | +9.4% |
| Mar 31, 2025 | $1.4B | +6.2% |
Revenue performance
The reported revenue rose during the quarter.
Quarterly comparison
Both the quarter-over-quarter and year-over-year comparisons were positive, with the year-over-year gain being more pronounced.
What to watch
The filing includes a discussion of risk factors and liquidity; any updates to those areas could be relevant.